Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

iBio (IBIO) Research & Development (2016 - 2025)

iBio (IBIO) has disclosed Research & Development for 16 consecutive years, with $4.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Research & Development rose 128.02% to $4.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $13.0 million, a 147.99% increase, with the full-year FY2025 number at $8.3 million, up 60.31% from a year prior.
  • Research & Development was $4.3 million for Q4 2025 at iBio, up from $3.6 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $4.3 million in Q4 2025 to a low of -$1.6 million in Q2 2022.
  • A 5-year average of $2.1 million and a median of $2.0 million in 2021 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: surged 431.22% in 2021, then tumbled 150.57% in 2022.
  • iBio's Research & Development stood at $1.9 million in 2021, then soared by 49.49% to $2.8 million in 2022, then tumbled by 44.76% to $1.5 million in 2023, then grew by 22.28% to $1.9 million in 2024, then soared by 128.02% to $4.3 million in 2025.
  • Per Business Quant, the three most recent readings for IBIO's Research & Development are $4.3 million (Q4 2025), $3.6 million (Q3 2025), and $3.2 million (Q2 2025).